Only Covaxin Gives 65.2% Efficacy Against COVID-19 Delta Variant: Lancet
The recent study by the Lancet peer-review said Covaxin surpassed all the vaccines in terms of efficacy against the Delta variant by providing 65.2% efficacy, said vaccine maker Bharat Biotech on November 12. The Lancet also said that it provides 77.8% efficiency against symptomatic patients. It provides ''70.8% protection against all variants of SARS-CoV-2 virus,'' said the maker. However, 12% of people experienced common side effects of the… read-more
Tags: Covid-19, Covaxin, Lancet, Bharat Bitotech, Study
Courtesy: Time Now News
Bharat Biotech's Covaxin Gets Guyana's Approval, Awaits WHO's Recognition
Guyana on November 2 announced that it has decided to add Bharat Biotech's Covaxin to its recognised list of COVID-19 vaccines. Notably, Australia also announced to recognise Covaxin as COVID-19 vaccine in its country on November 1. However, the company is still waiting for World Health Organisation's approval for Covaxin which will help it to get recognition from all the countries in the world.
Tags: Guyana, Covaxin, Bharat Bitotech, Covid-19, India
Courtesy: ANI